Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.
Center for Antimicrobial Resistance and Microbial Genomics and Gulf Coast Consortium on Antimicrobial Resistance.|Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA.|Genomics and Resistant Microbes Group, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
Jose M
JM
Munita
Center for Antimicrobial Resistance and Microbial Genomics and Gulf Coast Consortium on Antimicrobial Resistance.|Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Samuel L
SL
Aitken
Center for Antimicrobial Resistance and Microbial Genomics and Gulf Coast Consortium on Antimicrobial Resistance.|Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA.
William R
WR
Miller
Cleveland Veterans Affairs Medical Center Case Western Reserve University, Ohio.
Federico
F
Perez
Department of Medicine, Jackson Memorial Hospital, FL.|Division of Infectious Diseases, University of Miami Miller School of Medicine, Florida.
Rossana
R
Rosa
Department of Medicine, Jackson Memorial Hospital, FL.|Division of Infectious Diseases, University of Miami Miller School of Medicine, Florida.
Luis A
LA
Shimose
Division of Infectious Diseases, University of Miami Miller School of Medicine, Florida.
Paola N
PN
Lichtenberger
Department of Medicine, Jackson Memorial Hospital, FL.|Division of Infectious Diseases, University of Miami Miller School of Medicine, Florida.
Lilian M
LM
Abbo
Department of Pharmacy,  University of Texas McGovern Medical School, Houston.
Rupali
R
Jain
Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA.
Masayuki
M
Nigo
Department of Pathology and Laboratory Medicine, University of Texas McGovern Medical School, Houston.
Audrey
A
Wanger
Genomics and Resistant Microbes Group, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
Rafael
R
Araos
Center for Antimicrobial Resistance and Microbial Genomics and Gulf Coast Consortium on Antimicrobial Resistance.|Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA.
Truc T
TT
Tran
Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston.
Javier
J
Adachi
Division of Allergy and Infectious Diseases, University of Washington, Seattle.
Robert
R
Rakita
Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston.
Samuel
S
Shelburne
Cleveland Veterans Affairs Medical Center Case Western Reserve University, Ohio.
Robert A
RA
Bonomo
Center for Antimicrobial Resistance and Microbial Genomics and Gulf Coast Consortium on Antimicrobial Resistance.|Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA.|International Center for Antimicrobial Resistance, Universidad El Bosque, Bogota, Colombia.
Cesar A
CA
Arias
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D015780:Carbapenems / Q000494:pharmacology*; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012189:Retrospective Studies; D000078142:Tazobactam
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D002511:Cephalosporins; C519491:ceftolozane; D010397:Penicillanic Acid; D000078142:Tazobactam
P. aeruginosa; carbapenem resistant; ceftolozane; multidrug resistant